Hampshire International Business Park
Basingstoke, Hampshire, United Kingdom
+44-1256-894-000
http://www.shire.com
FTSE 100
#494 in
FT Global 500 (July 2012)
Shire is one of the UK's largest specialty biopharmaceutical companies. It has three main divisions: Specialty, Human Genetic Therapies, and Regenerative Medicine. Shire's roster includes attention deficit hyperactivity disorder (ADHD) treatments Vyvanse and Adderall XR; Pentasa and Lialda, both treatments for ulcerative colitis; as well as drugs for renal diseases and such rare genetic disorders as Fabry disease. Shire's portfolio also includes Carbatrol, a reformulation of a popular epilepsy drug; Alzheimer's disease drug Reminyl; and osteoporosis medication Calcichew. Headquartered in the UK, Shire does most of its business in North America, with sales forces that target specialist physicians.